PhotoCure ASAFRA:PHS -0.76%75 Return-on-Tangible-Equity is 122.70% as of Mar. 2026. GuruFocus rates FRA:PHS with a GF Score™ of 75/100 and a GF Value™ of €6.35 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 896 Drug Manufacturers companies, PhotoCure ASA ranks better than 88.39% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PhotoCure ASA's annualized net income for the quarter that ended in Mar. 2026 was €29.88 Mil. PhotoCure ASA's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €24.36 Mil. Therefore, PhotoCure ASA's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 122.70%.
The historical rank and industry rank for PhotoCure ASA's Return-on-Tangible-Equity or its related term are showing as below:
FRA:PHS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -35.98 Med: -6.37 Max: 33.96
Current: 33.96
During the past 13 years, PhotoCure ASA's highest Return-on-Tangible-Equity was 33.96%. The lowest was -35.98%. And the median was -6.37%.
FRA:PHS's Return-on-Tangible-Equity is ranked better than 88.39% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs FRA:PHS: 33.96
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
PhotoCure ASA Return-on-Tangible-Equity Related Terms
PhotoCure ASA Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHS vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 122.70% mean?
PhotoCure ASA (FRA:PHS) has a Return-on-Tangible-Equity of 122.70% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PhotoCure ASA and its competitors. According to the industry distribution chart, PhotoCure ASA ranks #104 out of 896 companies in the Drug Manufacturers industry, placing it in the top 11.6%.
Is PhotoCure ASA's Return-on-Tangible-Equity too high?
PhotoCure ASA's current Return-on-Tangible-Equity is 122.70%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.80. PhotoCure ASA's value of 122.70% is 1474.1% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #104 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PhotoCure ASA has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #104 out of 896 companies for Return-on-Tangible-Equity. This places PhotoCure ASA in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.80. PhotoCure ASA's value of 122.70% is 1474.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current Return-on-Tangible-Equity of 122.70% is 1474.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current Return-on-Tangible-Equity is 122.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.35, compared to a current price of €5.19 — trading 18.3% below its estimated fair value. The current Return-on-Tangible-Equity is 122.70% and 1474.1% above the Drug Manufacturers industry median of 7.80. PhotoCure ASA's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Return-on-Tangible-Equity is 122.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €5.19 is trading 18.3% below its estimated GF Value™ of €6.35.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
Return-on-Tangible-Equity: 122.70%
GF Value™: €6.35 vs. price of €5.19 (18.3% below fair value)
Industry Position: 1474.1% above the Drug Manufacturers median (#104 of 896)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
75GF Score
Get the complete analysis for FRA:PHS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
